Escitalopram: better treatment for depression is through the looking glass

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Dismrlers. Fourth Edition. American Psychiatric Association, Washington DC, USA (1994).
   Google Scholar
• Kerr EA, McGlynn EA, Van Vorst IKA et al Measuring antidepressant prescribing in a healthcare system using administrative data: implications for quality measurement and improvement. ft. Comm L. Qua'. Improv 26,203–216 (2000).
   PubMedGoogle Scholar
• Sartorius N. The economic and social burden of depression. J. Clin. Psychiatry 62\(Suppl. 15), 8–11 (2001).
   Google Scholar
• Kessler RC, Berglund P, Demler 0 et al The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). 161/1//A 289(23), 3095–3105 (2003).
   Google Scholar
• Keller MB. The long-term treatment of depression. J. Clin. P.Fhiatry60\(Suppl. 17), 41–50 (1999).
   Google Scholar
• Lesperance F, Frasure-Smith N. Depression in patients with cardiac disease: a practical review. J. Psychosom. Res. 48,379–391 (2000).
   PubMed Web of Science ®Google Scholar
• Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes: an epidemiological evaluation. Diabetes Cate 16,1167–1178 (1993).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Nelson CB, McGonagle IKA et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidty Survey. BE J. Psychiatry 168\(Suppl. 30), 17–30 (1996).
   Google Scholar
• Greenberg PE, Stiglin LE, Finkelstein SN et al The economic burden of depression in 1990../. Clin. Psychiatry54,405–419 (1993).
   Google Scholar
• Murray C, Lopez JL, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349,1436–1442 (1997).
   PubMed Web of Science ®Google Scholar
• Pinder R. Depression: the relevance of the time factor. J. Clin. fiychiatry 62 (Suppl. 15), 5–7 (2001).
   Google Scholar
• Shelton RC. The use of antidepressants in novel combination therapies. J. Clin. PTchiatry64\(Suppl. 2), 14–18 (2003).
   Google Scholar
• Thase ME. Effectiveness of antidepressants: comparative remission rates. I Clin. PTchiatry64\(Suppl. 2), 3–7 (2003).
   Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed patients. I Clin. PTchiatry63, 331–336 (2002).
   Google Scholar
• ••Describes escitalopram efficacy in afixed-dosed study.
   Google Scholar
• Hutt AJ, Tan SC. Drug chirality and its clinical significance. Drugs 52,1–12 (1996).
   PubMed Web of Science ®Google Scholar
• Tucker GT. Chiral switches. Lancet 355, 1085–1087 (2000).
   PubMed Web of Science ®Google Scholar
• Montgomery S, Loft H, Sanchez C et al. Escitalopram (s-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Phatmacol Toxical 88,282–286 (2001).
   PubMed Web of Science ®Google Scholar
• Wade A, Lemming OM, Hedegaard KB. Escitalopram 10mg/day is effective and well-tolerated in a placebo-controlled study in depression in primary care. Intl. Clin. PTchopharmacol 17,95–102 (2002).
   Google Scholar
• ••Describes escitalopram efficacy in afixed-dosed study.
   Google Scholar
• Sanchez C, Hogg S. The antidepressant effect of citalopram resides in the 5-enantiomer. Biol. fiychiatry 42 S88 (2000).
   Google Scholar
• Brocks DR, Jamali E Stereochemical aspects of pharmacotherapy. Phatmacothempy15,551–564 (1995).
   PubMed Web of Science ®Google Scholar
• Burke WJ, Kratochvil CJ. Stereoisomers in psychiatry: the case of escitalopram. I Clin. Psychiatry 4, 20–24 (2002).
   Google Scholar
• •Concise overview of stereochemistry as it specifically applies to escitalopram.
   Google Scholar
• Eichelbaum M. Enantiomers: implications and complications in developmental pharmacology. Dev. Pharmacol Ther. 18, 131–134 (1992).
   PubMedGoogle Scholar
• Wengel SP, Burke WJ. Escitalopram: what does it have to offer? Primary Psychiatry 10(1), 67–70 (2003).
   Google Scholar
• Caldwell J. Stereochemical determinants of the nature and consequences of drug metabolism. J. Chromatogr. 694,39–48 (1995).
   PubMed Web of Science ®Google Scholar
• Lane RM, Baker GB. Chirality and drugs used psychiatry: nice to know or need to know? Cell Mal Neurobial 19,355–372 (1999).
   PubMed Web of Science ®Google Scholar
• Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int. Clin. PTchopharmacol 10\(Suppl. 1), 15–21 (1995).
   Google Scholar
• Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. fiychiatry50, 345–350 (2001).
   Google Scholar
• Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mal Neurobial 19, 467–489 (1999).
   PubMed Web of Science ®Google Scholar
• Noble S, Benfield P RS-citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 8 (5), 410–431 (1997).
   Web of Science ®Google Scholar
• Robertson DW, Krushinski JH, Fuller RW, Leander JD. Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin uptake inhibitor. J. Med. Chem. 31, 1412–1417 (1988).
   PubMed Web of Science ®Google Scholar
• Wong DT, Threlkeld PG, Robertson DW. Affinities of fluoxetine, its enantiomers and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology5, 43–47 (1991).
   Google Scholar
• Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol Exp. Ther. 283,1305–1322 (1997).
   PubMed Web of Science ®Google Scholar
• Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. Pharmacol 340,249–258 (1997).
   PubMed Web of Science ®Google Scholar
• Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 17(5), 343–362 (2003).
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of escitalopram.
   Google Scholar
• Lexapro. Forest Pharmaceuticals, MO, USA (2002).
   Google Scholar
• Mork A, Kreilgaard M, Sanchez C. Escitalopram: in vitro and in vivo 5-HT uptake inhibition. Presented at the 12th World Congress of Psychiatry August 24-29, Yokohama, Japan (2002).
   Google Scholar
• Von Moltke LL, Greenblatt DJ, Giancarlo GM et al. Escitaloprarn (S-citalopram) and its metabolites in vitra cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug- Metab. Dispos. 29(8), 1102–1109 (2001).
   PubMed Web of Science ®Google Scholar
• Gutierrez MM, Rosenberg J, Abramowitz W An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin. Ther 25(4), 1200–1210 (2003).
   Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. PTchiatry134,382–389 (1979).
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J. Neural. Neurosurg. Psychiatry 23,56–62 (1960).
   PubMed Web of Science ®Google Scholar
• Guy W ECDEU Assessment Manual for Psychopharamacology. US Department of Health, Education, and Welfare publication (ADM) 76–338. National Institute of Mental Health, Rockville, MD, USA, 218–222 (1976).
   Google Scholar
• Endicott J, Nee J, Harrison Wet al Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 29,321–326 (1993).
   PubMed Web of Science ®Google Scholar
• Weissman M, Sholomskas D, Pottenger M et al Assessing depressive symptoms in five psychiatric populations: a validation study. Am. Epidemial 106,203–214 (1977).
   PubMed Web of Science ®Google Scholar
• Lepola U, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and welltolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol 18,211–217 (2003).
   Google Scholar
• •Highlights the efficacy of escitalopram in a flexible-dosed study.
   Google Scholar
• Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and RS-citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 7\(Suppl. 1), 40–44 (2002).
   Google Scholar
• ••Provides a good analysis of results from multiple studies of escitalopram in depression.
   Google Scholar
• Colonna L, Reines EH, Andersen HE Escitalopram is well-tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. hit.j Psych. Clin. Prac. 6,243–244 (2002).
   Google Scholar
• Rapaport MET, Bose A, Zheng H. Escitalopram prevents relapse of depressive episodes. Eur PTchiatry17\(Suppl. 1), 97 (2002).
   Google Scholar
• Wade A, Despiegel N, Reines E. Depression in primary care patients: improvement during long-term escitalopram treatment. J. Eur Neuropsychopharmacol 12\(Suppl. 3), S224 (2002).
   Google Scholar
• Montgomery SA, Huusom AKT, Bothmer J. Escitalopram is a new and highly efficacious SSRI in the treatment of major depressive disorder. J. Eur Neuropsychopharmacol 12\(Suppl. 3), S254 (2002).
   Google Scholar
• Bielski RJ, Ventura D, Chang C-C et al J. Eur Neuropsychopharmacol 13\(Suppl. 4), S262 (2003).
   Google Scholar
• Goodman WK, Bose A, Wang Q. Escitalopram 10 mg/day is effective in the treatment of generalized anxiety disorder. Poster presented at 156th Annual Meeting- of the American fiychiatric Association. May 17–22, San Francisco, CA, USA (2003).
   Google Scholar
• Bielski R, Bose A, Chang C et al. A double- blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Poster presented at 42nd Annual Meeting- of the American College of Neuropsychopharmacology December 7-11, San Juan, Puerto Rico (2003).
   Google Scholar
• Stahl S, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. Clin. Psychiatry 64,1322–1327 (2003).
   Google Scholar
• Kasper S, Loft H, Smith JR. Escitalopram is efficacious and well-tolerated in the treatment of SAD. Int. J. Neuropsychopharmacol 5\(Suppl. 1), S131 (2002).
   Google Scholar
• Hamilton M. The assessment of anxiety states by rating. BE J. PTchiatry32, 50–55 (1959).
   Google Scholar
• Sheehan D. The Anxiety Disease. Bantam Books, NY, USA, 113–117 (1986).
   Google Scholar
• Bandelow B, Broocks A, Pekrun G et al. The use of the Panic and Agoraphobia Scale (P&A) in a controlled clinical trial. Pharmacopsychiatry33, 174–181 (2000).
   PubMed Web of Science ®Google Scholar
• Liebowitz MR. Social Phobia. Mod. Pro& Pharmacopsychiatry22, 141–173 (1987).
   PubMedGoogle Scholar
• Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J. Clin. PTchiatry62\(Suppl. 15), 12–17 (2001).
   Google Scholar
• Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. PTchopharmacology134,319–329 (1997).
   Web of Science ®Google Scholar
• Sanchez C. Escitalopram: potent anxiolytic effects in rodent models of anxiety. New research abstracts of the 154th Annual Meeting of the American Bydriatric Association. May 9, New Orleans, LA, USA (2001).
   Google Scholar
• Mitchel PJ, Hogg S. Behavioral effects of escitalopram predict potent antidepressant activity. Biol. Bydriatry 47 (Suppl.), S88 (2000).
   Google Scholar
• Rosenthal MET, Li D. Efficacy and tolerability of escitalopram in patients intolerant of other SSRIs. Presented at the 12th World Congress of Psychiatry August 24-29, Yokohama, Japan (2002).
   Google Scholar